M

Metabolic Research Institute, Inc. | West Palm Beach, FL

Research site
(Unclaimed)
Location
1515 North Flagler Drive Suite 440, West Palm Beach, Florida, United States of America

Site insights

Top conditions

Top treatments

LY3298176
Finerenone
Tirzepatide
LY3502970
Orforglipron
Olezarsen
Povorcitinib
BMF-219
Insulin aspart
Sugar

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 15 total trials

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from ba...

Enrolling
Severe Hypertriglyceridemia
Drug: Olezarsen
Drug: Placebo

The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes a...

Enrolling
Type 2 Diabetes
Drug: Orforglipron
Drug: Semaglutide

The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to incre...

Active, not recruiting
Type 2 Diabetes
Drug: Tirzepatide
Drug: Dulaglutide

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide
Locations recently updated

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Enrolling
NonSegmental Vitiligo
Drug: Povorcitinib
Drug: Placebo
Locations recently updated

Researchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work pr...

Enrolling
Chronic Kidney Disease
Type 1 Diabetes Mellitus
Other: Placebo
Drug: Finerenone

Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known...

Enrolling
Chronic Kidney Disease
Type 2 Diabetes Mellitus
Drug: Finerenone (BAY94-8862 ) 20 mg
Drug: Finerenone Placebo

Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus.

Enrolling
Type 1 Diabetes Mellitus
Drug: BMF-219

Trial sponsors

Lilly logo
Bayer logo
Novo Nordisk logo
B
G
Incyte logo
I
Ionis Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems